Bombesin peptoids and peptides based PET probes for prostate cancer imaging
yang liu,hongguang liu,xiang hu,gang ren,kai cheng,jinbo li,wei huang,jiwon seo,annelise e barron,zhen cheng
2013-01-01
Abstract:557 Objectives Radiolabeled bombesin (BBN) analogs binding to gastrin-releasing peptide receptor (GRPR) are under actively studies for developing molecular probes for positron emission tomography (PET) of prostate cancer (PCa). In order to develop a clinic translatable BBN based PET probe, in this study a variety of BBN analogs including BBN(7-14) peptoids and peptides (RM1 and AMBA) were synthesized, radiolabeled and evaluated for their potential use in PCa PET imaging. Methods 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) conjugated BBN(7-14)-peptoid, four BBN peptide-peptoid hybrids, RM1, AMBA, and 1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA) conjugated RM1 and AMBA were synthesized and tested for their GRPR binding affinities. The DOTA-BBN(7-14)-peptoid, NODAGA-RM1, and NODAGA-AMBA were further radiolabeled with 64Cu and/or 18F-AlF. The resulted PET probes were then evaluated in subcutaneous PCa xenograft model (PC3) by small animal PET imaging and biodistribution. Results The BBN(7-14) peptoid and all the BBN peptide-peptoid hybrids showed no binding affinity to GRPR. PET and biodistribution results showed that 64Cu labeled BBN(7-14) peptoid could likely accumulate in the tumor nonspecifically. NODAGA-RM1 and NODAGA-AMBA can be successfully prepared and radiolabeled with 64Cu and 18F-AlF. Results showed that 64Cu and 18F-AlF labeled NODAGA-RM1 exhibit excellent in vitro serum stability and in vivo tumor imaging properties. The tumor uptake of 64Cu-NODAGA-RM1 was 3.3 ± 0.38 and 3.5 ± 1.0 %ID/g at 0.5 and 4 h p.i., and 18F-AlF-NODAGA-RM1 showed 4.6 ± 1.5 and 3.9 ± 0.48 %ID/g tumor uptake at 0.5 and 2 h, respectively. Conclusions Our studies indicate that developing BBN(7-14) peptoids for in vivo imaging is very challenge. On the contrary, the high tumor uptake and good pharmacokinetics highlight that 18F-AlF-NODAGA-RM1 is a promising probe for PET imaging of prostate cancer and has great potential in clinical applications. Research Support This work was supported, in part, by DOD-PCRP-NIA PC094646, NCI 5R01 CA119053 and In vivo Cellular Molecular Imaging Center (ICMIC) grant P50 CA114747.